PRODUCT INFORMATION



G0-C14

Item No. 37414

CAS Registry No.: 1510653-27-6

Formal Name: N-[2-[bis(2-hydroxytetradecyl)


aminolethyll-16-hydroxy-14-(2hydroxytetradecyl)-4,7-bis[3-[[2-[(2-hydroxytetradecyl)aminolethyl] amino]-3-oxopropyl]-10-oxo-

4,7,11,14-tetraazaoctacosanamide

MF: $\mathsf{C}_{106}\mathsf{H}_{216}\mathsf{N}_{10}\mathsf{O}_{10}$

1,790.9 FW: **Purity:** ≥90% Supplied as: A solid Storage: -20°C Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

G0-C14 is supplied as a solid. A stock solution may be made by dissolving the G0-C14 in the solvent of choice, which should be purged with an inert gas. G0-C14 is soluble (≥10 mg/ml) in methanol.

Description

G0-C14 is an ionizable cationic lipid that has been used in the generation of lipid nanoparticles (LNPs) for the delivery of siRNA in vitro and in vivo. Administration of LNPs containing G0-C14 and encapsulating siRNA targeting CaMKIIy increases plaque stability and promotes macrophage efferocytosis of apoptotic cells within plaques in a fat-fed Ldlr/- mouse model of atherosclerosis. LNPs containing G0-C14 and encapsulating siRNA targeting IL11 reduce fibrosis in a mouse model of bleomycin-induced pulmonary fibrosis when administered via inhalation.²

References

- 1. Huang, X., Liu, C., Kong, N., et al. Synthesis of siRNA nanoparticles to silence plaque-destabilizing gene in atherosclerotic lesional macrophages. Nat. Protoc. 17(3), 748-780 (2022).
- 2. Bai, X., Zhao, G., Chen, Q., et al. Inhaled siRNA nanoparticles targeting IL11 inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge. Sci. Adv. 8(25), eabn7162 (2022).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information Buyer agrees to purchase the material can be found on our website.

Copyright Cayman Chemical Company, 08/15/2025

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM